Tyra Biosciences Stock

tyra.bioHealthcare / BioTech & PharmaFounded: 2018Funding to Date: $157.64MM

Tyra Biosciences targets resistance in oncology with purpose built drugs for the benefit of patients.

Register To Buy and Sell Shares

For more details on financing and valuation for Tyra Biosciences, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access Tyra Biosciences’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Tyra Biosciences.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Register

Animation displayed is not current and securities are shown for illustrative purposes only.

News Highlights

Tyra Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, today announced the closing of its initial public offering of 12,420,000 shares of common stock, which includes the exercise in full by the underwriters of their option to purchase 1,620,000 additional shares, at an initial public offering price of $16.00 per share. The aggregate gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Tyra, were $198,720,000 million. Tyra's common stock is listed on the Nasdaq Global Select Market under the ticker symbol "TYRA."
Updated on: Apr 18, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.